stat sarepta - Search News

Order byBest matchMost fresh

Sarepta share price drops again

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a U.S. Food and Drug Administration advisory panel voted that risks tied to a GSK blood cancer drug outweighed the benefits demonstrated in trials, as concerns about sometimes serious ...

· 1d · on MSN

Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths

Clinical Trials Arena on MSN · 1d

Sarepta share price drops again after third gene therapy death

· 1d

Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says

The U.S. Food and Drug Administration is planning to request Sarepta Therapeutics (SRPT.O) to voluntarily stop all shipments of its gene therapy, Elevidys, a source familiar with the matter told Reut...

· 2d

FDA to ask Sarepta to stop shipping Duchenne gene therapy

· 1d

Sarepta Therapeutics crisis is huge blow to Duchenne families, company

Hoodline38m

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

NBC4 WCMH-TV on MSN1d

Sarepta Therapeutics lays off 500 employees amid FDA investigation, including 80 in Columbus

Sarepta Therapeutics announced it is laying off nearly 500 employees this week, including 80 at its Easton location. According to a mass layoff notice filed with the state, biotech company Sarepta Therapeutics laid off 80 employees Friday in central Ohio.

1don MSN

Sarepta Therapeutics laying off 80 employees in Ohio

Sarepta Therapeutics to lay off 493 workers, including 80 in Ohio, amid FDA probe, stock plunge, and concerns over Duchenne gene therapy Elevidys.

Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting

The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene therapy for Duchenne muscular dystrophy.

Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm downgrading SRPT stock from Hold to Sell.